Xenetic Biosciences Inc. (XBIO)
2.46
-0.13 (-5.02%)
At close: Apr 04, 2025, 3:46 PM
2.46
0.00%
After-hours: Apr 04, 2025, 04:00 PM EDT
-5.02% (1D)
| Bid | 2.3 |
| Market Cap | 3.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.57 |
| PE Ratio (ttm) | -0.96 |
| Forward PE | -6.21 |
| Analyst | n/a |
| Ask | 2.6 |
| Volume | 2,421 |
| Avg. Volume (20D) | 6,291 |
| Open | 2.53 |
| Previous Close | 2.59 |
| Day's Range | 2.46 - 2.53 |
| 52-Week Range | 2.26 - 5.20 |
| Beta | 2.18 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2016
Employees 2
Stock Exchange NASDAQ
Ticker Symbol XBIO
Website https://www.xeneticbio.com
2 weeks ago · accessnewswire.com
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsEncouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studie...
